Total | Female | Male | P-value | |
---|---|---|---|---|
# (%) | # (%) | # (%) | ||
Age (years) at ART start | 0.513 | |||
<=5 | 92 (52) | 45 (47) | 47 (58) | |
6–9 | 64 (36) | 38 (40) | 26 (32) | |
10–13 | 14 (7.9) | 9 (9.4) | 5 (6.2) | |
14–19 | 7 (4.0) | 4 (4.2) | 3 (3.7) | |
WHO status at cohort entry | 0.007 | |||
1 | 41 (23) | 13 (14) | 28 (35) | |
2 | 52 (29) | 32 (33) | 20 (25) | |
3 | 72 (41) | 43 (45) | 29 (36) | |
4 | 11 (6.2) | 8 (8.3) | 3 (3.7) | |
Missing | 1 (0.6) | 0 (0.0) | 1 (1.2) | |
CD4 count at cohort entry† | 0.625 | |||
< 200 | 34 (19) | 22 (23) | 12 (15) | |
200–350 | 14 (7.9) | 6 (6.3) | 8 (9.9) | |
351–500 | 12 (6.8) | 7 (7.3) | 5 (6.2) | |
> 500 | 65 (37) | 33 (34) | 32 (40) | |
Missing | 52 (29) | 28 (29) | 24 (30) | |
Current ART regimen | 0.090 | |||
First-line treatment | 139 (79) | 80 (83) | 59 (73) | |
Second-line treatment | 38 (21) | 16 (17) | 22 (27) | |
Mean time (years) on any ART regimen, SD | 6.6 (2.7) | 6.7 (2.7) | 6.5 (2.4) | 0.703 |
Mean time (years) on current ART regimen, SD | 2.1 (1.0) | 2.3 (1.0) | 1.9 (0.8) | 0.010 |